|
End-of-day quote
NSE India S.E.
2026-09-21
|
5-day change | 1st Jan Change | ||
| 2,009.30 INR | +0.27% |
|
+1.54% | +47.26% |
| 09-16 | Gilead Sciences Expands Licensing Agreements for HIV Treatment | MT |
| 08-06 | Emcure Pharmaceuticals Limited, Q1 2027 Earnings Call, Aug 06, 2026 |
Company Valuation: Emcure Pharmaceuticals Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| Market Cap 1 | 203,202 | 302,490 | 381,124 | - | - |
| Change | - | 48.86% | 26% | - | - |
| Enterprise Value (EV) 1 | 208,106 | 306,160 | 387,508 | 377,846 | 365,626 |
| Change | - | 47.12% | 26.57% | -2.49% | -3.23% |
| P/E | 29.4x | 32.7x | 32x | 25.9x | 21.6x |
| PBR | 4.57x | - | 6.26x | 5.1x | 4.17x |
| PEG | - | 1x | 1.1x | 1.1x | 1.1x |
| Capitalization / Revenue | 2.57x | 3.29x | 3.6x | 3.18x | 2.84x |
| EV / Revenue | 2.64x | 3.33x | 3.66x | 3.16x | 2.73x |
| EV / EBITDA | 14.2x | 17.1x | 18x | 14.9x | 12.6x |
| EV / EBIT | 19.2x | 22.3x | 22.8x | 18.4x | 15.2x |
| EV / FCF | 33x | 52.5x | 39.1x | 32x | 24.5x |
| FCF Yield | 3.03% | 1.9% | 2.56% | 3.12% | 4.08% |
| Dividend per Share 2 | 3 | 3.6 | 4.007 | 4.728 | 5.773 |
| Rate of return | 0.28% | 0.23% | 0.2% | 0.24% | 0.29% |
| EPS 2 | 36.43 | 48.77 | 62.72 | 77.55 | 92.93 |
| Distribution rate | 8.23% | 7.38% | 6.39% | 6.1% | 6.21% |
| Net sales 1 | 78,960 | 92,035 | 105,929 | 119,687 | 133,996 |
| EBITDA 1 | 14,689 | 17,890 | 21,583 | 25,399 | 29,101 |
| EBIT 1 | 10,847 | 13,740 | 16,973 | 20,531 | 24,113 |
| Net income 1 | 6,813 | 9,244 | 11,870 | 14,586 | 17,577 |
| Net Debt 1 | 4,904 | 3,670 | 6,384 | -3,278 | -15,498 |
| Reference price 2 | 1,072.40 | 1,595.50 | 2,009.30 | 2,009.30 | 2,009.30 |
| Nbr of stocks (in thousands) | 189,483 | 189,590 | 189,680 | - | - |
| Announcement Date | 5/22/25 | 5/5/26 | - | - | - |
1INR in Million2INR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 31.95x | 3.65x | 17.91x | 0.2% | 3.96B | |
| 32.78x | 11.92x | 24.16x | 0.6% | 1,028B | |
| 30.03x | 6.68x | 18.7x | 1.99% | 651B | |
| 33.38x | 7.81x | 16.15x | 2.6% | 466B | |
| 19.33x | 4.72x | 11.71x | 2.81% | 346B | |
| 19.72x | 5.16x | 12.79x | 3.11% | 266B | |
| 21.26x | 4.42x | 12.58x | 1.99% | 259B | |
| 24.43x | 6.42x | 11.43x | 2.62% | 208B | |
| 12.52x | 4.56x | 9.46x | 4.01% | 191B | |
| -45.4x | 6.61x | 25.81x | 2.19% | 186B | |
| Average | 18.00x | 6.19x | 16.07x | 2.21% | 360.57B | |
| Weighted average by Cap. | 23.69x | 7.72x | 17.83x | 1.99% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- EMCURE Stock
- Valuation Emcure Pharmaceuticals Limited
Select your edition
All financial news and data tailored to specific country editions
